Publications by authors named "Phil Jeffrey"

Claim this Profile
T
The validation and clinical bioanalysis of the Bicycle® Toxin Conjugate zelenectide pevedotin in human plasma.
Joseph A Tweed, Fern Adams-Dam, Justin Bader, Ying Zhang, Jane Allanson, Phil Jeffrey

Bioanalysis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioanalysis of the Bicycle toxin conjugate BT5528 and released monomethyl auristatin E via liquid chromatography-tandem mass spectrometry.
Joseph A Tweed, Fern Adams-Dam, Jane Allanson, Kevin Holmes, Ryan Senior, Phil Jeffrey

Bioanalysis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma E Mudd, Helen Harrison, Phil Jeffrey

Mol Cancer Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer.
Gemma E Mudd, Heather Scott, Liuhong Chen, Katerine van Rietschoten, Gabriela Ivanova-Berndt, Phil Jeffrey

J Med Chem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology.
Punit Upadhyaya, Julia Kristensson, Johanna Lahdenranta, Elizabeth Repash, Jun Ma, Phil Jeffrey

J Med Chem· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BT7480, a novel fully synthetic tumor-targeted immune cell agonist™ ( TICA™) induces tumor localized CD137 agonism.
Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Eric Haines, Heather Cohen, Phil Jeffrey

J Immunother Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease.
Kelly M Knee, Reema Jasuja, Amey Barakat, Dharani Rao, Zane Wenzel, Phil Jeffrey

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression and regulation of drug transporters in vertebrate neutrophils.
Matthew J Foulkes, Katherine M Henry, Julien Rougeot, Edward Hooper-Greenhill, Catherine A Loynes, Phil Jeffrey

Sci Rep· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADME SARfari: comparative genomics of drug metabolizing systems.
Mark Davies, Nathan Dedman, Anne Hersey, George Papadatos, Matthew D Hall, Phil Jeffrey

Bioinformatics· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs.
Roger N Gunn, Scott G Summerfield, Cristian A Salinas, Kevin D Read, Qi Guo, Phil Jeffrey

J Cereb Blood Flow Metab· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the blood-brain barrier in CNS drug discovery.
Phil Jeffrey, Scott Summerfield

Neurobiol Dis· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Receptor occupancy and brain free fraction.
Jeanette Watson, Sara Wright, Adam Lucas, Kirsten L Clarke, Jean Viggers, Phil Jeffrey

Drug Metab Dispos· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery DMPK: changing paradigms in the eighties, nineties and noughties.
Scott Summerfield, Phil Jeffrey

Expert Opin Drug Discov· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability.
Nicolas Charrier, Brian Clarke, Leanne Cutler, Emmanuel Demont, Colin Dingwall, Phil Jeffrey

J Med Chem· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction.
Scott G Summerfield, Kevin Read, David J Begley, Tanja Obradovic, Ismael J Hidalgo, Phil Jeffrey

J Pharmacol Exp Ther· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational sciences-turning drug-like molecules into medicines.
Phil Jeffrey, Eric Karran, Alan Palmer, Geoffrey Stemp

Drug News Perspect· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro prediction of brain penetration - a case for free thinking?
Scott G Summerfield, Phil Jeffrey

Expert Opin Drug Discov· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier.
Leanne Cutler, Colin Howes, Nigel J Deeks, Tania L Buck, Phil Jeffrey

J Pharm Sci· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.
Scott G Summerfield, Alexander J Stevens, Leanne Cutler, Maria del Carmen Osuna, Beverley Hammond, Phil Jeffrey

J Pharmacol Exp Ther· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis